Comparison of Buserelin to Danazol Therapy in Endometriosis

  • A. Lemay
  • HRPI buserelin protocol 310 study group

Abstract

Although the etiology of endometriosis is not understood, it is known that the ectopic endometrial tissue is sensitive to the production of sex steroid hormones during the menstrual cycle. Endometriosis is rare before menarche and develops usually during the reproductive years. The importance of ovarian steroids in the development and maintenance of endometriosis is also demonstrated by the usual curative effect of oophorectomy and the spontaneous regression of the disease at menopause. Experimentally implanted endometriosis in castrated monkeys requires sex steroids for its maintenance [1].

Keywords

GnRH Agonist Serum Estradiol Serum Estradiol Level Endometriotic Tissue Clinical Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dizerega, GS, Barber, DL, and Hodgen, GD (1980). Endometriosis: Role of ovarian steroids in initiation, maintenance and suppression. Fertil Steril, 33, 649PubMedGoogle Scholar
  2. 2.
    Bergquist, A, Ljungberg, O, and Myhre, E (1984). Comparison of the histological appearance of human endometrium and endometriotic tissue obtained simultaneously: A preliminary report. Acta Obstet Gynecol Scand (Suppl), 123, 11CrossRefGoogle Scholar
  3. 3.
    Janne, O, Kauppila, A, and Kokko, E (1981). Estrogen and progestin receptors in endometriotic lesions: comparison with endometrial tissue. Am J Obstet Gynecol, 141, 562PubMedGoogle Scholar
  4. 4.
    Tamaya, T, Motoyama, T, and Ohono, Y (1979). Steroid receptor levels and histology of endometriosis and adenomysis. Fertil Steril, 31, 396PubMedGoogle Scholar
  5. 5.
    Vihko, R, Isotalo, H, and Kauppila, A (1984). Hormonal regulation of endometrium and endometriosis tissue. In: Raynaud, JP (ed.) “Medical Management of Endometriosis”, p 79. (New York: Raven Press)Google Scholar
  6. 6.
    Kistner, RW (1958). The use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol, 75, 264PubMedGoogle Scholar
  7. 7.
    Kistner, RW (1959). The treatment of endometriosis by inducing pseudopregnancy with ovarian hormones: a report of 58 cases. Fertil Steril, 10, 539Google Scholar
  8. 8.
    Dmowski, WP, and Cohen, MR (1978). Antigonadotropin (danazol) in the treatment of endometriosis. Am J Obstet Gynecol, 130, 41PubMedGoogle Scholar
  9. 9.
    Barbieri, RL, Evans, S, and Kistner, RW (1982). Danazol in the treatment of endometriosis: analysis of of 100 cases with a 4-year follow-up. Fertil Steril, 36, 737Google Scholar
  10. 10.
    Buttram, VC, Reiter, RC, and Ward, S (1985). Treatment of endometriosis with danazol: report of a six year prospective study. Fertil Steril, 43, 353PubMedGoogle Scholar
  11. 11.
    Lemay, A, and Quesnel, G (1982). Potential new treament of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril, 38, 376PubMedGoogle Scholar
  12. 12.
    Shaw, RW, Fraser, HM, and Boyle, H (1983). Intranasal treatment with luteinizing hormone releasing hormone agonist in women with endometriosis. Brit Med J, 287, 1667CrossRefGoogle Scholar
  13. 13.
    Pring, DW, Maresh, M, and Fraser, AC (1983). Luteinizing hormone releasing hormone agonist in women with endometriosis. Brit Med J, 287, 1718CrossRefGoogle Scholar
  14. 14.
    Lemay, A, Maheux, R, Faure, N, Jean, C, and Fazekas, ATA (1984). Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril, 41, 863PubMedGoogle Scholar
  15. 15.
    Schriock, E, Monroe, SE, Henzl, M, and Jaffe, RB (1985). Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril, 44, 583PubMedGoogle Scholar
  16. 16.
    Zorn, JR, Tanger, Ch, Roger, M, Grenier, J, Comaru-Schally, AM, and Schally, AV (1986). Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: A preliminary study in eight women with endometriosis. Int J Fertil, 3, 11Google Scholar
  17. 17.
    Hardt, W, Schimdt-Gollwitzer, M, Schmidt-Gollwitzer K, Genz, T, and Nevinny-Stickel, J (1986). Erst ergebnisse bei der behandlung der endometriose mit dem LH-RH-analogon buserelin. Geburtsh u Frauenheilk, 46, 483CrossRefGoogle Scholar
  18. 18.
    Steingold, KA, Cedars, M, Ju, JKH, Rändle, D, Judd, HL, and Meldrum, OR (1987). Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol, 69, 403PubMedGoogle Scholar
  19. 19.
    Lemay, A, Maheux, R, Huot, C, Blanchet, J, and Faure, N (1988). Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol (in press)Google Scholar
  20. 20.
    American Fertility Society (1979). Classification of endometriosis. Fertil Steril, 32, 633Google Scholar
  21. 21.
    Fraser, IS, Markham, R, Mcllveen, J, and Robinson, M (1982). Dynamic tests of hypothalamic and pituitary function in women treated with danazol. Fertil Steril 37, 484PubMedGoogle Scholar
  22. 22.
    Dmowski, PW, Headley, S, and Radwanska, E (1983). Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women. Fertil Steril, 39, 49PubMedGoogle Scholar
  23. 23.
    Rannevik, G, and Thorell, JI (1984). The influence of danazol on pituitary function and on the ovarian follicular hormone secretion in premenopausal women. Acta Obstet Gynecol Scand (Suppl), 123, 89CrossRefGoogle Scholar
  24. 24.
    Hardt, W, and Schmidt-Gollwitzer, M (1983). Sustained gonadal suppression in fertile women with the LHRH agonist buserelin. Clin Endocrinol, 19, 613CrossRefGoogle Scholar
  25. 25.
    Meldrum, DR, Pardridge, WM, Karow, WG, Rivier, J, Vale, W, and Judd, HL (1983). Hormonal effects of danazol and medical oophorectomy in endometriosis. Obstet Gynecol, 62, 480PubMedGoogle Scholar
  26. 26.
    Holt, JP, and Keller, D (1984). Danazol treatment increases serum enzyme levels. Fertil Steril, 41, 70PubMedGoogle Scholar
  27. 27.
    Cann, CE, Henzl, M, Burry, K, Andreko, J, Hanson, F, Adamson, D, Trobough, G, and Strewler, G (1986). Reversible bone loss is induced by GnRH agonist. 68th Annual Meeting of the Endocrine Society, Anaheim, California, AbstractGoogle Scholar
  28. 28.
    Matta, WH, Shaw, RW, Hesp, R, and Katz, D (1987). Hypogonadism induced by luteinizing hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Brit Med J, 294. 1523CrossRefGoogle Scholar
  29. 29.
    Devogelaer, JP, DeDeuxchaisnes, CN, Donnez, J, and Thomas, K (1987). LHRH analogues and bone loss. The Lancet, I, 1498CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • A. Lemay
    • 1
    • 2
    • 3
  • HRPI buserelin protocol 310 study group
  1. 1.Endocrinology of ReproductionHospital Saint-Francoise D’AssiseCanada
  2. 2.Hoechst—Roussel Pharmaceuticals Inc.SomervilleUSA
  3. 3.Hoechst Canada Inc.MontrealCanada

Personalised recommendations